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The approaches to quantitatively assessing the health risks of
chemical exposure have not changed appreciably in the past 50 to
80 years, the focus remaining on high-dose studies that measure
adverse outcomes in homogeneous animal populations. This
expensive, low-throughput approach relies on conservative
extrapolations to relate animal studies to much lower-dose human
exposures and is of questionable relevance to predicting risks to
humans at their typical low exposures. It makes little use of a
mechanistic understanding of the mode of action by which
chemicals perturb biological processes in human cells and tissues.
An alternative vision, proposed by the U.S. National Research
Council (NRC) report Toxicity Testing in the 21
st Century: A Vision and
a Strategy, called for moving away from traditional high-dose
animal studies to an approach based on perturbation of cellular
responses using well-designed in vitro assays. Central to this vision
are (a) ‘‘toxicity pathways’’ (the innate cellular pathways that may
be perturbed by chemicals) and (b) the determination of chemical
concentration ranges where those perturbations are likely to be
excessive, thereby leading to adverse health effects if present for a
prolonged duration in an intact organism. In this paper we briefly
review the original NRC report and responses to that report over
the past 3 years, and discuss how the change in testing might be
achieved in the U.S. and in the European Union (EU). EU
initiatives in developing alternatives to animal testing of cosmetic
ingredients have run very much in parallel with the NRC report.
Moving from current practice to the NRC vision would require
using prototype toxicity pathways to develop case studies showing
the new vision in action. In this vein, we also discuss how the
proposed strategy for toxicity testing might be applied to the
toxicity pathways associated with DNA damage and repair.
Introduction
The goal of toxicitytestingshould be the collection ofappropriate
results from test systems in order to assess the likely risks posed to
human populations atambientexposurelevels; i.e.,provide the data
inputs necessary for a realistic assessment of human risk.
Traditionally, these objectives were met by high-dose testing in
experimental animals with specific approaches for extrapolation
from high to lower doses and from the experimental animals to the
human population. Modern toxicology has incorporated techniques
emerging from the field of molecular biologyinthe 1980sand 1990s
for assessment of modes of action and target identification.
However, the gold standard against which toxicity testing methods
are evaluated has remained largely unchanged over the past five
decades: organism-level responses (e.g., hepatotoxicity, cancer,
reproductive/developmental toxicity, and neurotoxicity) deemed
to serve as measures of adverse responses in high-dose studies with
homogeneous groups of laboratory animals.
In the U.S., extrapolation from these high-dose animal toxicity
tests to expected responses in humans from low-dose chemical
exposure is based on a variety of uncertainty factors or on linear
extrapolations through a zero dose. Not surprisingly, there has
been broad disaffection with this approach from both regulatory
agencies and regulated communities. These traditional methods
are expensive, exorbitant in their use of animals, and have low
throughput. Although over the past 30 years there have been
attempts to incorporate pharmacokinetics and modes of action for
certain high-value or high-liability compounds into the risk
assessment process, these research efforts have been costly and
have had limited success in changing the existing regulatory
framework. In addition, most of these research efforts have focused
more on explaining high-dose rodent effects than on understand-
ing the biological basis for dose-response relationships expected in
humans exposed to chemicals at relevant environmental levels.
In response to these concerns, in 2004 the U.S. Environmental
Protection Agency (U.S. EPA) and the National Toxicology
Program of the U.S. National Institute of Environmental Health
Sciences commissioned a committee of the National Academy of
Sciences to evaluate current toxicity testing methods and
recommend changes that would take into account the new
understanding of human biology and emerging testing technolo-
gies. The culmination of the work of the committee on toxicity
testing for environmental agents was a report issued by the U.S.
National Research Council (NRC) in 2007: Toxicity Testing in the
21
st Century: A Vision and a Strategy (TT21C) [1]. At the center of the
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reorientation of such testing to evaluating the responses of toxicity
pathways, i.e., normal cellular signaling pathways that can be
perturbed by chemical exposures, in well-designed in vitro assays
using human cells. This new paradigm would replace the current
approach of relying almost exclusively on high-dose phenotypic
responses in animals.
The new approaches based on evaluation of in vitro assays that
cover a range of toxicity pathways would enable testing across
large concentration ranges for multiple modes of action and
provide sufficient sensitivity for detection of biological effects at
low concentrations unobtainable with conventional animal studies.
The schematic of the components involved in this vision (Figure 1)
includes toxicity pathway testing, limited targeted testing in
animals required until a comprehensive suite of pathway tests is
completed and validated, and dose-response and extrapolation
modeling for interpreting the in vitro assay results for assessment of
risk to human health. That the committee was not tasked to
develop alternatives to animal testing is a point deserving of some
emphasis. Rather, it was directed to design an appropriate,
modern approach to toxicity testing. In the final analysis, the
committee argued that in vitro assays using human cells or tissue
surrogates would be much preferred to conventional studies with
animals; nonetheless, one of the testing design criteria stressed in
its report was to use the fewest animals necessary in the most
humane manner if targeted in vivo testing was pursued.
New directions in toxicity testing from the European
Union
During the time frame that the National Academy of Sciences
committee was in deliberation, regulatory changes in the Euro-
pean Union (EU) were moving the testing of cosmetics ingredients
toward the elimination of animal testing altogether. Notably, the
European 7
th Amendment to the Cosmetics Directive (passed in
2003) has restricted the use of animal tests for a variety of end
points [2]. An initial ban on acute toxicity testing in animals,
including in vivo genotoxicity testing, came into effect in 2009. By
2013 the legislation will dictate that no animal tests (including
repeat-dose studies, reproductive toxicity testing, and carcinoge-
nicity bioassays) can be conducted on cosmetic ingredients
intended for the European market.
Elsewhere, breakthrough thinking on how to address this issue
paralleled the NRC report. Fentem and colleagues, for example,
have highlighted the need for a paradigm shift in toxicology to risk
assessments that support decisions about consumer safety without
the need to generate data through animal tests [3]. Their
approach was based on the concept that information derived
from existing and new non-animal models can be interpreted in
terms of potential for human pathology, following realistic
exposure levels, rather than replacement of animal tests on a
like-for-like basis.
Problems faced by EU cosmetics manufacturers in
assessing genotoxicity
As a result of the European 7
th Amendment (2003) [2] there is
now a ban in the EU on animal testing for the assessment of
genotoxic effects of chemical ingredients intended for cosmetic
products. In practical terms, this has meant the cessation of several
tests, including the widely used bone marrow micronucleus assay
in rodents [4]. For now, however, the possibility remains for
incorporating the micronucleus end point into repeat-dose general
(systemic) toxicology assessments in rodents along with other
genetic toxicology end points such as the Comet assay, but only
until 2013 [5]. Although the 2-year rodent cancer bioassay is very
rarely used in the testing of cosmetic ingredients, this is also
included in the 2013 ban. These changes leave the cosmetics
industry with an innovation-constrained and uncompetitive
dilemma. First, in vitro-only genetic toxicology assay strategies
have a high irrelevant-positive rate [6,7], and many common
biochemical products (including those derived from food, e.g.,
flavonoids) [8,9], would be erroneously rejected for commerce if in
vitro regulatory tests alone were used. The high false-positive rate
Figure 1. Schematic of components required to implement the new vision of toxicity testing in the 21
st century (needs permission
from NRC TT21C report). The core components of the TT21C vision relate to testing for biological activity of compounds in toxicity pathway assays
and to dose-response and extrapolation modeling using computational systems biology and pharmacokinetic tools. In the period of transition from
current practice to the new vision some targeted testing in animals might be required. Targeted testing might also allow evaluation of target
pathways and identification of metabolites. Assessing likely metabolism remains a challenge for the full implementation of the TT21C vision.
doi:10.1371/journal.pone.0020887.g001
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these assays are used purely in a hazard identification mode, the
label of ‘‘genotoxicity,’’ applied to a chemical by the tests
irrespective of dose, would lead to the rejection of that chemical
if no follow-up testing is conducted.
To see in vitro genetic toxicology tests as the problem, however,
is to miss the important point that they are in fact one of the most
refined sets of tools available to toxicologists to define the human
pathology concern (cancer) in terms of the toxicity pathways that
may precede it; i.e., mutagenicity, clastogenicity, and aneugenicity.
It is only the lack of a dose-response element in the use of genetic
toxicology tests that limits their current use in risk assessment. This
discrepancy should be the focus of research in this area from the
TT21C perspective in order to overcome the obstacles of
extrapolating from in vitro to in vivo. A problem in this respect is
the current underutilization of information on the biological
mechanisms for genotoxicity and on the homeostatic processes
that attenuate the effects at low doses in the whole organism. Only
by recognizing the current limitations in the understanding of
these processes and by embracing computational modeling that
mechanistically addresses the effects of low-dose perturbations will
we be able to move forward.
The disciplines of genetic toxicology and assessment of risk for
carcinogenicity are clearly prime candidates for change in line
with the TT21C vision. Genetic toxicology has long involved the
use of in vitro assays for primary assessment, but in keeping with the
ban on in vivo follow-up tests on cosmetic ingredients the model for
the future is an exclusive reliance on in vitro tests without
confirmatory animal studies for carcinogenicity or in vivo
mutations. Hence, the drive to alternatives in the EU and in the
US vision of TT21C, while developed for different requirements –
sparing animals versus redesign of test methods – are following
very similar trajectories and have reached a similar position with
respect to the changes needed in toxicology.
US activities subsequent to publication of the NRC report
In 2008, the U.S. EPA Office of Research and Development,
the National Toxicology Program at the U.S. National Institute of
Environmental Health Sciences, and the U.S. National Chemical
Genomics Center initiated a partnership to advance toxicity
testing towards the goals espoused in the NRC report [10]. A
‘‘Future of Toxicity Testing Workgroup’’ was announced in a
2008 paper in Science to design a research strategy that would move
the science and technology used in toxicity testing away from
reliance on high-dose animal testing towards high-throughput in
vitro assays designed to detect perturbations in toxicity pathways
[10]. The paper stressed that high-throughput in vitro screening
assays could be used for (a) prioritizing chemicals for in vivo testing,
(b) predicting the results of animal studies, and (c) assisting in risk
assessment. While this interagency initiative calls for relatively
modest changes compared to the full TT21C vision of having
appropriately designed in vitro assays as the core element of risk
assessment, many of the steps outlined for assay design, technology
implementation, and database development are essential for any
program that aims to replace animal testing with suites of in vitro
assays.
In another development, the U.S. EPA has published The U.S.
Environmental Protection Agency’s Strategic Plan for Evaluating the Toxicity
of Chemicals (http://www.epa.gov/spc/toxicitytesting/). This report calls
for a stepwise approach for developing in vitro testing for chemical
screening as well as the development of ‘‘virtual tissue’’
computational models for predicting toxicity, leading eventually
to using their results for various risk management decisions [11].
Broader interest in the TT21C vision
Two of the National Academy of Sciences committee members
recently described the key attributes of the NRC report as part of a
commentary in Toxicological Sciences [12]. In addition, the journal’s
editors provided an overview of the NRC report [13] and invited
seven commentaries from researchers in various sectors of the
toxicology community [14,15,16,17,18,19,20]. These articles
appeared in the journal throughout 2009 and in early 2010, and
discussed the benefits and shortcomings of the new scientific
methods outlined in the NRC report for toxicity testing and risk
assessment. The commentaries expressed different degrees of both
support and skepticism for the TT21C vision, and described many
of the scientific challenges and changes needed to make the vision
a reality. The two authors from the National Academy of Sciences
committee had an opportunity to respond to these varied
perspectives [21].
Some overarching issues emerged from the commentaries: (a)
Because not all responses observed in in vitro assays will be adverse,
how will a determination be made as to which of the responses
obtained warrant attention from a risk assessment perspective? (b)
Because in vivo responses frequently require multi-tissue interactions
that will be absent from in vitro testing assays, how can apical
responses in intact mammalian systems be predicted on the basis of
in vitro data? (c) Given that the ultimate goal of characterizing risk is
the establishment of a recommended guidelinefor human exposure,
traditionally done by extrapolation of animal toxicity data to
humans (see Figure 2A), why was the NRC report silent on the
manner inwhichin vitro results would be used forderivingguidelines
forhumanexposurebasedonperturbationsoftoxicitypathways?(d)
Finally, how can such fundamental, pervasive changes in the way
we test for toxicity (Figure 2B) be achieved in a smooth, efficient
manner? Are such changes even possible given the rather
hidebound regulatory environment? In the present article we
comment on each of these issues in the context of developing an
example ofa humanrisk/safetyassessment based on examinationof
a toxicity pathway associated with DNA damage.
Results and Discussion
Examining a prototype pathway: DNA-damage repair
The gold standard for predicting carcinogenicity is the 2-year
rodent bioassay. Although it has evolved somewhat over time, this
test has become standardized by the U.S. National Toxicology
Program. In its standard protocol, this program conducts 2-year
bioassays in two species (rats and mice), beginning treatments at 5–
6 weeks of age in both sexes with three doses and a control. The 2-
year bioassay is supported by preliminary shorter-term animal
studies that evaluate data on absorption, distribution, metabolism,
and excretion that are important to setting the dose. The highest
dose tested is a maximum tolerated dose (MTD), with half or one
quarter of the MTD usually selected as additional doses. The
MTD is estimated from the short-term studies and is operationally
defined as the highest dose that does not significantly increase
lethality or induce more than a 10% weight loss when compared to
controls.
The use of the MTD is usually justified by the argument that
high doses increase the likelihood of seeing a response given the
group sizes used, i.e., about 100. Unfortunately, the MTD
frequently induces biological responses (such as cytotoxicity) that
will not occur at lower doses in animals or humans. The induction
of irrelevant responses in rodents exposed at high doses creates a
significant problem of interpretation, i.e., separating those effects
that are due only to high doses from those that would persist at
lower levels of exposure. This interpretive problem is made more
Toxicity Pathway-Based Chemical Risk Assessment
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rodent carcinogens.
Cancer modes of action
Carcinogenicity is believed to result from a progressive
accumulation of mutations that select for a growth/survival
advantage in affected cells. In defining in vitro tests for detecting
carcinogens the goal has been to identify and quantify alterations
in the molecular pathways associated with the generation and
fixation of mutations. The two major categories of chemical
carcinogens are DNA-reactive carcinogens (genotoxic carcinogens) and
non-genotoxic carcinogens that alter DNA indirectly through other
effects on the cell [22]. Genotoxic carcinogens, or their
metabolites, are usually electrophiles that can directly react with
DNA to form adducts, and thus they can directly initiate the
neoplastic transformation of a normal cell. On the other hand,
non-genotoxic carcinogens can act through pathways associated
with the modulation of reactive oxygen species, proliferation,
apoptosis, endocrine controls, or immune surveillance to promote
pre-initiated tumor formation. Risk assessment procedures treat
genotoxic carcinogens as having no threshold, while non-
genotoxic carcinogens are considered to have a threshold, leading
to regulation of these chemicals through the use of safety factors.
This distinction between genotoxic and non-genotoxic carcinogens
is important in establishing exposure guidelines for chemicals.
Unfortunately,thebulk ofthe immensebody ofmechanisticwork
conducted to study carcinogenic responses for risk assessment has
been restricted to the manner of extrapolating to lower doses (linear
versus threshold) or to determining that certain rodent cancers
shouldnotberegarded asrelevant forhumans(such ashydrocarbon
nephropathy in male rats, or thyroid tumors in rats associated with
enhanced clearance of thyroid hormone). The challenge faced with
mode-of-action studies in vivo or with the proposed in vitro toxicity
pathway assays is to bring a fundamentally new perspective to dose-response
extrapolation rather than to simply choose between linear low-dose
and threshold approaches. Ideally, the new assays for toxicity testing
and for test interpretation should provide information to allow
mechanistic prediction of the shape of the dose-response curve over
broad ranges of concentration, thereby enabling assessment of a
point of departure for risk assessment.
Figure 2. Comparison of current (A) and proposed (B) toxicity testing paradigms. The current approach (Panel A) to setting regulatory
standards involves interpretation of the most sensitive end point observed in animal studies. Low-dose extrapolation requires obtaining a point of
departure from the results of the animal studies and the use of either linear or threshold extrapolation plus application of uncertainty factors to the
point of departure. Other extrapolations between species or across exposure routes are sometime conducted with pharmacokinetic modeling of the
tissue doses that are associated with adverse effects. A similar sequence of steps can be envisioned for setting standards based on pathway assays
(Panel B). Likely hazards are determined by the sensitivity of the various toxicity pathway assays; extrapolations require assessing adverse
consequences of in vitro exposures and use of computational systems biology pathway (CSBP) and pharmacokinetic modeling to set a standard for
human exposure related to mg/kg/day ingested or ppm (parts per million) in the inhaled air.
doi:10.1371/journal.pone.0020887.g002
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reactive compounds
The goal of toxicity testing should not be to predict high-dose
outcomes in rodents but rather the more accurate prediction of the
likely risks of low-dose exposures in human populations. With
respect to mechanistic dose-response behaviors for DNA-reactive
compounds, it would be necessary to assess the conditions under
which perturbations of DNA structure are expected to propagate
into fixed mutations in the genome and provide altered cells with
the potential for autonomous growth. Identifying this transition
from the condition where DNA-repair processes can control any
induced damage to one where there are sufficiently large degrees of
damage leading to mutations [23] would be a key step in assessing
‘‘adversity’’ at the cellular level for DNA-reactive compounds.
Consistent with the procedures presented in the NRC report,
the risk/safety assessment of chemicals with potential impact on
human health, e.g. ingredients in cosmetics, should start with an
initial assessment of the nature of the chemical and the expected
levels of human exposure. All available information needs to be
taken into account, such as read-across to similar molecules,
QSAR (quantitative structure-activity relationship) alerts, and any
other available data. If genotoxicity testing is required, a test-
battery covering mutation, clastogenicity and aneuploidy would be
adequate as the initial part of the test protocols for in vitro toxicity
pathways. A broader suite of pathway assays would provide a
catalogue of likely modes of action and of the relative ability of
compounds to activate particular pathways based on their potency
(by identifying an effective concentration causing 50% or 10%
maximum responses, i.e., an EC50 or EC10). Such screening over
multiple molecular targets is common with pharmaceutical
compounds and has been pursued by the U.S. EPA in its ToxCast
program [24]. Comparison of EC50s or EC10s across a suite of
inclusive pathway assays will allow for identification of primary
mode(s) of action for low-dose exposures. For instance, compounds
that are found to have lower EC50s in DNA–reactivity-oriented
assays than in assays for other toxicity pathways would be
considered likely to have mutagenic and carcinogenic potential as
the primary mode of action in humans with low-dose exposures.
For cases where higher EC50s are found for mutagenicity than for
other pathway activation, the conclusion would be that mutage-
nicity is likely to be a secondary effect, with primary modes of
action suggested by more sensitive pathways such as oxidative
stress or activation of receptor-mediated pathways.
However, this enumeration of activities across a suite of tests,
and the doses at which they produce perturbations of pathways,
would not by itself define ‘adversity’ at a cellular or molecular
level; instead it would only define likely hazards. This consider-
ation of all pathway assay EC50s would provide a more qualitative
assessment of likely apical outcomes and a relative measure of in
vitro potency, but conclusions about adversity will require a more
quantitative integration of the results of pathway assays examining
different aspects of DNA–damage-and-repair pathway function.
Degrees of perturbations as a measure of adversity in
vitro
Toxicology has long made use of in vitro test batteries to predict
specific toxicity to target organs. The goal of mode-of-action,
human biology-based testing should not be to generate batteries of
tests to provide a prediction of test results on animal toxicity for
various end points. Instead, these methods should be intended to
determine regions of exposure that will not cause any adverse
responses in exposed human populations. These panels of assays,
evaluating specific pathway targets such as DNA damage and
repair, would be designed to capture increasing degrees of
perturbation (Figure 3). The scheme shown in Figure 3 would
require several types of assays for increasing severity or a single
assay that could evaluate different regions of response. Each test in
the panel would be designed to provide dose-response over broad
ranges of treatment and assess some aspect of pathway
perturbation for DNA damage, DNA repair, and mutation. The
organization of these perturbations across levels of biological
response could be incorporated into an engineering ‘‘failure
model’’ [20] or for use in a more quantitative process as in genetic
progression and waiting-time models [25]. In either of these
modeling approaches, the degree of perturbation and adversity
would be measured by a composite probability incorporating the
contributions from the sequential stages of increasing pathway
activation obtained by dose-response characterization of the
pathway assays. The overall goal in such an aggregate analysis is
to estimate, with some degree of confidence, regions of exposure
with no increase in the frequency of mutation, as a result of
integrated control through DNA repair, cell cycle delay or arrest,
and apoptosis.
In a very real sense, the point about evaluating regions of
exposures that are expected to be without effect, i.e., to be safe, is a
departure from the current practice of estimating risks from high-
dose animal exposures. The wording of an exposure recommen-
dation would be that a compound with a mutagenic, DNA–
reactivity-related mode of action is likely to cause cancer with
prolonged, higher-dose exposures in humans. However, there
would not be a quantitative estimate of risk, as is now the standard
practice after determining the incidence of cancer in animals
exposed to high doses of the test compound.
Dynamic pathways underlying biological response
The biological effects of a chemical or hazardous substance at
the level of individual cells are mediated by cognate ‘‘receptor’’
molecules and downstream signaling and transcriptional networks
(toxicity pathways). The subsequent changes in the state and
dynamic behavior of these networks form the basis of the
particular shape of the dose-response curve for specific phenotypic
end points. There appear to be a finite, small number of core stress-
response pathways that are activated by cells in response to various
chemical stimuli to maintain homeostasis, or to make specific cell-
fate decisions like apoptosis [26]. Examples include the oxidative
stress response, heat-shock response, DNA-damage response,
hypoxia, and endoplasmic reticulum stress pathways – all of
which feature a common architecture consisting of a transcription
factor, a ‘‘sensor,’’ and a ‘‘transducer’’ and are present in all cell
types of an organism [26] (Figure 4A). Typically activated at
concentrations of chemicals significantly lower than those that lead
to adverse effects at the organism level, this suite of pathways can
be assayed as a group to serve as predictors of potential cell
damage [26,27]. A second group of toxicity pathways are those
related to activation of specific endogenous receptor pathways,
such as estrogen, androgen, and thyroid hormone signaling.
These canonical stress-response pathways are in turn made up
of a core set of functional regulatory network motifs that underlie
cellular homeostasis, decision making, and phenotypic transitions.
Discovered from detailed investigation of transcriptional regula-
tory networks in the bacterium Escherichia coli [28] and the budding
yeast Saccharomyces cerevisiae [29], these motifs all have a
characteristic structure and the capacity to perform specific
information-processing functions [30,31,32] (Figure 4B). Examples
include (a) negative feedback, which enables homeostasis and
acceleration of response time in gene circuits [33,34]; (b) positive
feedback, which generates switching behavior between multiple
Toxicity Pathway-Based Chemical Risk Assessment
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20887Figure 4. Stress response pathways and network motifs. (A) Typical structure of a stress response pathway (adapted from Simmons et
al. [26]). The so-called eight canonical stress response pathways, conserved broadly across eukaryotes, have a common structure (common motifs) for
sensing damage and mounting a transcriptional response to counteract the stress. (B) Common network motifs in intracellular response
pathways. Three elements, (genes/proteins) X, Y, and Z, in a pathway can regulate each other to form: (i) a negative feedback loop; (ii) a positive
feedback loop; (iii) a coherent feed-forward loop, where X activates Y, and both X and Y activate Z; and (iv) an incoherent feed-forward loop, where
X activates both Y and Z, but Y suppresses Z. Two transcription factors X and Y can regulate each other through, for instance: (v) a double-negative
feedback loop; or (vi) a double-negative feedback loop with positive autoregulation. Sharp arrows denote activation; flat arrows denote suppression.
doi:10.1371/journal.pone.0020887.g004
Figure 3. A schematic figure illustrating progressive activation of a prototype toxicity pathway, with attendant discrete phenotypic
transitions. Text on right of figure shows proposed approaches for characterizing discrete transitions through multiple cellular phenotypes, i.e., (1)
basal function, (2) minimally perturbed cellular states, (3) upregulation of adaptive, homeostatic gene batteries, and finally (4) overtly adverse states
with excessive pathway perturbations. The structure of the circuitry with various embedded, nonlinear feedback loops is schematized in the middle
panels. In the context of in vitro assay design, varying free concentrations of a test compound in the test media lead to increasing activation of
pathway component (signaling protein) A, thereby driving pathway perturbations of signaling components B and C, and further signaling events
downstream of C. Each of these steps is expected to be associated with specific alterations in gene expression, phenotypic read-out and pathway
activation, identified by CSBP modeling. As the concentration increases, various portions of the network would be sequentially activated until full
activation was achieved (indicated by progressively darker shading of pathway components). Full pathway activation triggers a robust response
throughout the pathway circuitry, leading to adverse outcomes measurable in the cellular assay.
doi:10.1371/journal.pone.0020887.g003
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introduce a time delay in activation as well as detect persistence in
the activating signal [36]; and (d) the incoherent feed-forward loop,
which can function as a pulse generator and response accelerator
[37,38]. These motifs can also act in combination to generate
more complex regulatory patterns in transcriptional networks [30].
Similar motifs have been identified in the cells of higher organisms
– for example in the circuits that control gene expression in the
pancreas and the liver [39] as well as the regulatory circuits of
human embryonic [40] and hematopoietic [41,42] stem cells.
Understanding the organization and quantitative behavior of these
circuits, which are likely to be key components underlying toxic
response, should lead to improved prediction of the cellular
outcome of specific perturbations introduced by various chemicals.
The advent of the ‘‘-omics’’ era has enabled detailed character-
ization of the molecular signatures associated with particular
perturbed or disease states. However, a mechanistic understanding
of the underlying biological processes will require more- focused
quantitative analysis of specific pathways and network motifs derived
from these large-scale molecular signatures [43]. In particular,
understanding the dynamic behavior of toxicity pathways will
require stimulation of these pathways at a number of time points
and at various concentrations of the activating chemical, rather
than static snapshots of the molecular state [44]. Computational
systems biology pathway (CSBP) models are expected to play a key
role in this process, allowing mechanistic prediction of the dose-
response based on pathway dynamics. Crucial to the intermediate
objective of estimating in vitro adversity, CSBP models need to
include the molecular circuits responsible for the basal operation
of toxicity pathways in the absence of an external chemical
stressor. The basal dynamics set up the background state from
which additional perturbations will occur as the stress level
increases. Quantitative characterization of the network circuits
(from in vitro assays) will dictate the changes in response from
basal state to activation. A properly implemented CSBP model
would take such changes into account to predict the range of
concentrations of stressors that would not produce appreciable
adversity. Another advantage to development of these CSBP
models would be the ability to assess pathway components that
display polymorphisms in the human population to help identify
sensitive subpopulations.
Computational systems biology of DNA-damage
response networks
In recent years there has been a great deal of progress in
computational modeling of cellular response networks to predict
their dose-response behavior (see http://www.thehamner.org/
education-and-training/drm_workshop.html). In mammalian cells,
the tumor suppressor protein p53 functions as an essential
guardian of genomic stability – mutations in p53 are associated
with nearly half of all cancers. DNA damage activates p53 through
sensor molecules such as ataxia telangiectasia mutated (ATM).,
Activated p53 in turn transcriptionally regulates several key
pathways that cooperatively limit the increase in mutation
frequency in affected cells (Figure 5) [45]. It is likely that p53
upregulates a number of DNA repair enzymes and itself acts as a
component of the repair complex to enhance removal of damaged
DNA products [46]. By transcriptionally activating p21 and other
regulatory proteins, p53 also puts a brake on the cell cycle engine
to arrest the cell at various mitotic stages [47]. What seems also
important is that before the relatively slow p53-dependent
transcriptional regulation is fully launched, several p53-indepen-
dent post-translational mechanisms can be quickly activated to
immediately delay/arrest the cell cycle [48,49,50]. The resulting
slowdown or outright blockade of cell proliferation not only allows
more time for DNA repair but also reduces the probability of
mutation, because DNA replication is almost always required for
DNA damage to become a heritable mutation. Therefore even
though the tendency to mutate increases as a result of increased
DNA damage, if cell proliferation rate is also reduced accordingly,
there may not be any tangible increase in overall mutation
frequency. If the degree of DNA damage in the cell is too severe to
be effectively repaired, strongly activated p53 triggers the
apoptosis pathway to eliminate the cell, which could otherwise
mutate at a potentially dangerous high frequency [51].
It thus appears that perturbed cells use an incoherent feed-
forward mechanism to control mutagenesis (Figure 5): the cell
cycle arrest and apoptosis pathways together form the inhibitory
arm, while DNA damage serves as the stimulatory arm (see also
Figure 4B iv). Depending on the degrees of nonlinearity of the two
arms, an incoherent feed-forward motif may generate either
perfect adaptation or a non-monotonic response [52,53], which
can lead respectively to threshold behavior or to hormetic dose-
response for mutagenesis/carcinogenesis [54]. Therefore, to
understand the changes in mutation frequency in cells exposed
to a particular concentration of genotoxic chemical, it is necessary
to examine, in addition to DNA damage, the degree of activation
of the pathways underlying DNA repair, cell cycle arrest, and
apoptosis.
Understanding the time-dependent alterations in mutation
frequency after exposure to genotoxic agents requires knowledge
Figure 5. p53-mediated perturbation of DNA damage response
pathways that affect mutagenesis. A negative feedback motif
composed of p53, Mdm2, and others (not shown) can produce
undamped oscillations in response to radiation-induced double strand
breaks. A partial AND (pAND) gate is used to indicate that to produce
inheritable mutations, both DNA damage and cell proliferation (DNA
replication) are required, and that the two processes likely contribute to
mutagenesis in a multiplicative manner. Activation of the apoptosis
pathway works to mitigate mutagenesis by killing cells with severe or
unrepairable DNA damage. Pointed arrows indicate activation and
blunted arrows indicate inhibition.
doi:10.1371/journal.pone.0020887.g005
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revealed rich dynamic behaviors in this pathway [55]; besides
driving a number of the pathways described above, activated p53
can upregulate murine double minute 2 (Mdm2), a regulatory
protein that promotes the degradation of p53 through the
ubiquitin-proteasome pathway [56]. This negative feedback motif,
together with other feedback regulations involving wild-type p53-
induced phosphatase (WIP1), ATM, and checkpoint kinase 2
(CHK2) [57], generates oscillatory behavior of p53 and Mdm2 in
response to DNA double-strand breaks induced by c-irradiation
[58,59]. Interestingly, despite variations in pulse amplitude and
period, the undamped oscillation of p53 activity in individual cells
appears to be digital: (a) pulse amplitude and period are generally
independent of the severity of DNA damage; and (b) cells either
undergo uninterrupted oscillations at a characteristic frequency or
do not oscillate at all, with the fraction of oscillating cells
increasing with the dose of irradiation [58]. It remains to be seen,
however, whether p53 oscillation is a conserved dynamic pattern
in response to various genotoxic chemicals.
At this time the biological function of p53 oscillations is unclear.
It is possible that multiple p53 pulses serve to measure the time
elapsed subsequent to the onset of DNA damage. In that case,
prolonged oscillation could act as a signal for persistent damage,
triggering activation of the apoptotic pathway. Rigorous quanti-
tative studies of p53 dynamics in the context of differential
activation of DNA repair, cell cycle arrest, and apoptosis pathways
are urgently required. To determine the low–dose- response
behavior for mutation and the point of departure to adversity, it is
also essential to understand how the p53 circuit behaves at basal
conditions with only background DNA damage, and how its
behavior is altered with increasing DNA damage under exposure
to genotoxic chemicals. A recent study has suggested that at basal
conditions p53 oscillates infrequently in a manner that is loosely
coupled to the cell cycle without causing unnecessary cell cycle
arrest [60]. A computational systems biology modeling approach
that incorporates the oscillatory p53 and Mdm2 circuit in
association with perturbations to downstream pathways for DNA
repair, cell cycle, and apoptosis may allow a quantitative,
mechanistic examination of regions of adequate repair function




The combination of carefully designed in vitro assays and CSBP
models of the structure and function of toxicity pathways can
provide an estimate of the concentrations of chemicals in vitro that
likely lead to excessive perturbation of the pathways. This
concentration would comprise a redefined point of departure for
risk assessment (Figure 2B). The process of setting acceptable
exposure levels requires the ability to estimate human exposures
that would give rise to tissue or blood (or plasma) concentrations
equal to those concentrations found to be ‘adverse’ in in vitro assays
with human cells. Such calculations would require contributions
from the discipline of pharmacokinetic modeling, and more
specifically, physiologically based pharmacokinetic modeling. In
particular, a reverse dosimetry approach [61,62] can be used to
estimate the ranges of exposure expected to give rise to specific
plasma or tissue concentrations. The overall process of moving
from perturbations of a suite of toxicity pathways to a health risk
assessment will require three different components: (a) appropri-
ately designed in vitro toxicity pathway assays, (2) CSBP
(computational systems biology pathway) models for extrapolation
to lower in vitro concentrations, and (3) pharmacokinetic tools to
convert active concentrations in vitro to expected human exposures
that would yield equivalent tissue concentrations in exposed
individuals.
Implementing TT21C Toxicity Pathway-based
Approaches
Three of the four key issues described earlier in this contribution
in association with the NRC report: defining adversity, setting
regulatory standards, and predicting toxicity, have been addressed
above with the example of DNA-damage response. Adversity would
be defined in relation to degrees of perturbation above basal stress/
functional levels, while regulatory standards would be based on the
active in vitro concentration and extrapolations with CSBP and
pharmacokinetic model structures. The new approach will not be
intended to predict risk in the particular quantitative fashion as is
currently done. Today, based on high-dose responses, we estimate a
dose expected to be associated with some degree of risk, e.g., 1 per
1,000,000. In contrast, the pathway approach would predict safe
regions of exposures, e.g., those where perturbations will be insufficient
to cause adverse outcomes at the cellular or organism level.
We are left with the last of the four issues raised earlier: how to
make change of this magnitude occur in the face of a long tradition
of in vivo testing for assessing the hazards of chemicals for humans.
These new approaches, based on mode of action, human biology,
and a better appreciation of biological responses to stressors and
pathway perturbation, promise improved throughput and reduced
uncertainty in estimating the concentrations that cause various
degrees of perturbation. Nonetheless, they will naturally be
compared, in one way or another, to current approaches such as
existing cancer bioassays to determine whether the new methods
provide adequate safety for exposed human populations. The
comparison of past practice and these more mode–of-action-based
approaches will be difficult, but, in our opinion, can be made by
using well-studied prototype compounds whose toxicity has
already been examined with in vivo and in vitro assays (Figure 6).
These prototype compounds can support case studies for proof-
of-concept exercises to evaluate mechanistic, toxicity–pathway-
based approaches to the assessment of risks to human health. The
choice of the prototype chemicals should be dictated by the
specific stress pathways under consideration, e.g., DNA damage,
endoplasmic-reticulum stress, and oxidative stress [26]. Alterna-
tively, the chosen compound could have specific receptor-
mediated targets – such as the estrogen receptor, the aryl
hydrocarbon receptor, or the peroxisomal proliferator activating
receptor (PPARs). These case studies could be more broadly useful
in assessing how mode-of-action results should be used to inform
risk assessment. Another value of these prototypes/case studies will
be demonstration of the new TT21C paradigm in practice –
showing how data would be collected, organized, and interpreted
to make decisions about regions of exposure not expected to be
associated with appreciable risk in human populations. Our
laboratories are now actively pursuing various prototype studies
examining DNA damage, oxidative stress, and PPAR-a signaling.
Conclusions
A recent special issue of the Journal of Toxicology and Environmental
Health contains reprints of the entire NRC report [63] and the
EPA strategic plan proposed in response [64], as well as 14 articles
discussing specific scientific tools that will become the foundation
of the methods outlined in the TT21C vision [65,66,67,68,
69,70,71,72,73,74,75,76,77,78]. The tools discussed include com-
putational systems biology (CSB) methods for pathway analysis
[78] and ‘‘virtual tissue’’ models for predicting toxicity [76]. The
Toxicity Pathway-Based Chemical Risk Assessment
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response [21] to the nine commentaries in Toxicological Sciences
previously discussed, two members of the National Academy of
Sciences committee noted that at the time of writing in early 2010,
there had been some 75 presentations worldwide on the NRC
report and the TT21C vision (these presentations were listed in
supplementary materials of their article). In many ways, this
proposed transformation of toxicity testing from the NRC report
appears more and more to be an idea whose time has come. The
transformation towards an in vitro, toxicity pathway test approach
is especially timely and necessary in terms of the Seventh
Amendment to the Cosmetics Directive in the EU and the
looming reauthorization of the Toxic Substances Control Act in
the US and the REACH program in the EU. REACH
(Registration, Evaluation, Authorization and Restriction of
Chemical substances) is a new EU regulation on chemicals and
their safe use (EC 1907/2006) that went into force on June 1,
2007. Without a redirection of toxicity testing, these broad
initiatives will require a large amount of conventional high-dose
toxicity testing of questionable relevance for ensuring human
safety in the use of chemicals. The TT21C paradigm provides a
blueprint for change. Specific examples, such as the case study
with the DNA–damage-repair pathway outlined here, will be
instrumental in guiding these changes in designing new methods
for testing toxicity and the tools such as CSBP and pharmacoki-
netic models necessary for interpretation of test results for assessing
human safety.
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